Table 3.

The effect of PPI use on survival in patients with pancreatic cancer

	Crude HR (95%CI)	adjusted1 HR (95% CI)
Former users	1.15 (0.94–1.40)	1.12 (0.92–1.37)
Short-term, active users	1.11 (1.02–1.21)	1.11 (1.02–1.21)
Intermediate-term, active users	0.96 (0.82–1.11)	0.95 (0.82–1.11)
Long-term, active users	1.03 (0.94–1.14)	1.02 (0.93–1.13)

N=, number of individuals; HR, hazard ratio; 95% CI, 95% confidence interval;

¹Adjusted for: diabetes, smoking, alcohol use and obesity

Stratification:

1. former users: most recent PPI prescription >6 months prior to index date
2. active users: most recent PPI prescription < 6 months prior to index date

   1. short-term, active users: first prescription <12 months before the index date
   2. intermediate-term, active users: first prescription 12 – 24 months before the index date
   3. long-term, active users: first prescription >24 months before index date